News tagged with avastin

Related topics: food and drug administration · breast cancer · ovarian cancer · cancer drugs · drug

Avastin no benefit to older lung cancer patients: study

(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report.

Apr 17, 2012
popularity0 comments 0

FDA finds more vials of fake cancer drug

(AP) -- The Food and Drug Administration is warning doctors that a second counterfeit version of the best-selling cancer drug Avastin has been found in the U.S., packaged as the Turkish brand of the medication.

Apr 04, 2012
popularity0 comments 0

System to catch fake drugs has idled for years

(AP) -- The news this week that a fake version of the cancer medicine Avastin has made its way into the United States highlights a longtime concern: There are few safeguards to make sure fake drugs can be spotted before ...

Feb 16, 2012
popularity0 comments 0

Counterfeit drugs becoming big business worldwide

(AP) -- The discovery that a fake version of the widely used cancer medicine Avastin is circulating in the United States is raising new fears that the multibillion-dollar drug-counterfeiting trade is increasingly making ...

Feb 16, 2012
popularity0 comments 1


Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.

Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.

Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed